Home / Treatments / Oncotype Dx Prostate Cancer Assay
Oncotype Dx Prostate Cancer Assay denials: what the review data shows
Independent reviewers have decided 14 published cases where an insurer denied Oncotype Dx Prostate Cancer Assay — and they overturned the insurer 71.4% of the time. A denial for Oncotype Dx Prostate Cancer Assay is a starting position, not a final answer.
Published decisions
14
2001–2026
Overturned
71.4%
10 denials reversed
By condition
Published outcomes when Oncotype Dx Prostate Cancer Assay was denied for these conditions.
| Condition | Decisions | Overturned |
|---|---|---|
| Prostate Cancer | 12 | 75% |
How to use this in your appeal
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Oncotype Dx Prostate Cancer Assaywhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.